Evaluating the prevalence of transthyretin amyloidosis in heart failure patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess how often transthyretin amyloidosis (ATTR) occurs in patients aged 65 and older with heart failure with preserved ejection fraction (HFpEF). Participants will undergo a 99mTc-pyrophosphate SPECT scan, along with blood sample collection and various assessments related to their heart failure symptoms and quality of life. The study will also review electronic health records to track hospitalization and survival outcomes over five years. The goal is to identify ATTR in heart failure patients earlier to facilitate timely treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a confirmed diagnosis of HFpEF.
* Age ≥65 years old

Exclusion Criteria:

* End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
* no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
* Negative 99mTc-pyrophosphate scan within a year
* Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
* Known diagnosis of amyloidosis
* Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Hanna K Gaggin, MD — Massachusetts General Hospital
• Study coordinator: Abbie Macher, BS
• Email: ajmacher@mgh.harvard.edu
• Phone: 617-643-6328

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• LY3971297 in heart failure: safety and tolerability in HF with preserved and reduced ejection fraction

  This study tests how well LY3971297 is tolerated and what side effects occur in people with HFpEF or HFrEF.

  Recruiting Phase 1 Eli Lilly and Company · Detroit, Michigan and 11 other locations · NCT07547540

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Preventing transthyretin amyloidosis in young carriers of a genetic variant

  This study is testing if a medication called acoramidis can help prevent transthyretin amyloidosis in young adults who carry a specific genetic variant that puts them at risk for the disease.

  Recruiting at 104 sites Phase 3 Eidos Therapeutics, a BridgeBio company · La Jolla, California and 103 other locations · NCT06563895

• Evaluating Iodine-124 Evuzumitide in Patients with Systemic Amyloidosis

  This study is testing how a new imaging agent called iodine-124 evuzumitide works in people with systemic amyloidosis, especially those with heart issues, to see how it affects their organs and overall health.

  Recruiting Phase 2 Oregon Health and Science University · Portland, Oregon · NCT05758493

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.